Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia

Leukemia & Lymphoma 2018

Publish date:: November 9, 2018

Key clinical point: Zanubrutinib, a BTK inhibitor, appears effective against Waldenström macroglobulinemia in an early study.

Major finding: Zanubrutinib had an overall response rate of 92%, and the estimated 12-month progression-free survival rate was 89%.

Study details: A phase 1 study with 73 patients evaluable for efficacy in this analysis.

Disclosures: The trial is sponsored by BeiGene. Dr. Tam reported financial relationships with BeiGene and other companies.

Read the article.

Citation:

Leukemia & Lymphoma 2018

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Indolent Lymphoma

Follicular lymphoma treatment can benefit patients 80 years and older,

Survival Data Reported From Largest CAR T Trial in B-Cell Lymphoma,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

R2 appears active in high-risk FL and MZL,

In situ vaccination produced responses in indolent NHL,

All Specialties